LYCOS RETRIEVER 
Imitrex: Migraines
built 635 days ago
Imitrex® (sumatriptan succinate) is a prescription medication that is used to treat migraine headaches. Imitrex will not help to prevent migraines, but it can help to treat a migraine that is already occurring. The injectable form of Imitrex is ... approved for the acute treatment of cluster headaches.
Source:
Imitrex is a headache medicine. It is believed to work by narrowing the blood vessels around the brain. Imitrex ... reduces substances in the body that can trigger headache pain, nausea, sensitivity to light and sound, and other migraine symptoms.
Source:
Imitrex (Sumatriptan) is an antimigraine medicine. Migraine headaches are believed to result from dilatation of the blood vessels in the head. Sumatriptan causes constriction of the blood vessels... relieving migraine headache.
Source:
How much Imitrex medicine you take and how often you take it depends on many factors, including the condition being treated, your age, and weight. If you have any questions about the amount and/or frequency of the medicine you are taking, talk with your health care provider. Carefully read the information provided with Imitrex and reread it each time you get this prescription refilled. Take Imitrex exactly as prescribed by your health care provider. Imitrex is intended to relieve acute migraine headaches. Do not use it to prevent or reduce the number of attacks you experience.
Source:
Trexima for Migraine: Developed in collaboration with Pozen, Trexima, an innovative formulation combining the active ingredient in Imitrex - the current market leader - and naproxen sodium, is expected to provide superior efficacy compared to each of the individual components alone. In a Phase II trial, the combination of Imitrex and naproxen sodium relieved pain more effectively than either agent administered alone, both at the 2-hour time point, and on a sustained basis from 2-24 hours. Filing is expected in 2H2005.
Source:
Two further studies, both parallel-group, placebo-controlled trials were conducted involving a total of 628 migraine patients who received 4 mg SC injections of Imitrex (4). The studies demonstrated a significant difference in patients treated with Imitrex compared to placebo. However, the efficacy of the higher (6 mg) dose evaluated in the U.S. trial (2) was demonstrated to be higher without a significant increase in frequency or severity of adverse events.
Source:
MORE ABOUT
Migraines